Clinical Trial Detail

NCT ID NCT02484430
Title TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

acute lymphocytic leukemia

Therapies

Sapanisertib

Age Groups: adult

No variant requirements are available.